Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix

PHASE3CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Uterine Cervical DysplasiaPapillomavirus Infections
Interventions
DRUG

AV2

"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."

DRUG

Placebo

"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."

Trial Locations (1)

Route Kimwenza n°23

Centre de Santé Lisungi, Kinshasa

All Listed Sponsors
collaborator

University of Kinshasa

OTHER

collaborator

University Hospital, Antwerp

OTHER

lead

Jean-Pierre Van geertruyden

OTHER

NCT02346227 - Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix | Biotech Hunter | Biotech Hunter